User:Mr. Ibrahem/Deucravacitinib

Deucravacitinib, sold under the brand name Sotyktu, is a medication used to treat moderate to severe plaque psoriasis. It should not be used with other strong immunosuppressants. It is take by mouth.

Common side effects include upper respiratory infections, herpes simplex, folliculitis, and acne. Other side effects may include allergic reactions, infection, cancer, and muscle breakdown. Use in pregnancy is of unclear safety. Use is not recommended in those with significant liver problems. It is a TYK2 inhibitor.

Deucravacitinib was approved for medical use in the United States in 2022. As of 2022 it is not approved in Europe or the United Kingdom. In the United States it costs about 6,200 USD per month.